CD274 and neoplasm: In a retrospective exploratory analysis of the results of the KEYNOTE 224 trial [43] on the effect of second-line pembrolizumab in HCC, baseline PD-L1 expression on Tumor cells (TC) also did not affect response rates to pembrolizumab treatment.